Evaxion A (EVAX) Income from Continuing Operations (2020 - 2026)
Evaxion A (EVAX) posted Income from Continuing Operations of 4061000.0 for Q1 2026, up 36.83% quarter-over-quarter from 6429000.0 in Q4 2025, and down 106.77% year-on-year from 59968451.13 in Q1 2025.
Evaxion A (EVAX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Evaxion A (EVAX) has reported Income from Continuing Operations for 7 consecutive years, with 4061000.0 the latest figure, recorded in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 4061000.0, down 106.77% year-over-year; the trailing twelve-month figure through Mar 2026 was 11624000.0 (up 21.81% YoY), and the FY2025 annual result was 9523000.0, up 21.58% from the prior year.
- Income from Continuing Operations was 4061000.0 for Q1 2026 at Evaxion A, up from 6429000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 4087000.0 in Q3 2025 and troughed at 7218000.0 in Q4 2022.
- Average Income from Continuing Operations over 5 years is 4361882.35, with a median of 5221000.0 recorded in 2025.
- The widest YoY moves for Income from Continuing Operations: up 292.15% in 2025, down 359.1% in 2025.
- Over 5 years, Income from Continuing Operations stood at 7218000.0 in 2022, then soared by 32.43% to 4877000.0 in 2023, then rose by 14.31% to 4179000.0 in 2024, then slumped by 53.84% to 6429000.0 in 2025, then surged by 36.83% to 4061000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 4061000.0 in Q1 2026, 6429000.0 in Q4 2025, and 4087000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | 74.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -14.46 Mn |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 227.36 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 1.03 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -4.45 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 378.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 205.99 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | -453.82 Mn |
| 10 | Evaxion A | 1.33 Bn | 1.33 Bn | - | -4.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.06 Mn |
| Dec 31, 2025 | -6.43 Mn |
| Sep 30, 2025 | 4.09 Mn |
| Jun 30, 2025 | -5.22 Mn |
| Mar 31, 2025 | -1.96 Mn |
| Dec 31, 2024 | -4.18 Mn |
| Sep 30, 2024 | -2.13 Mn |
| Jun 30, 2024 | -6.60 Mn |
| Mar 31, 2024 | 758,000.00 |
| Dec 31, 2023 | -4.88 Mn |
| Sep 30, 2023 | -6.07 Mn |
| Jun 30, 2023 | -6.13 Mn |
| Mar 31, 2023 | -6.63 Mn |
| Dec 31, 2022 | -7.22 Mn |
| Sep 30, 2022 | -6.09 Mn |
| Jun 30, 2022 | -5.12 Mn |
| Mar 31, 2022 | -6.29 Mn |
| Dec 31, 2021 | -5.72 Mn |
| Sep 30, 2021 | -6.10 Mn |
| Jun 30, 2021 | -8.16 Mn |